Concurrent validity of provisional remission criteria for gout: a dual-energy CT study

[1]  N. Dalbeth,et al.  Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual‐Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial , 2019, Arthritis & rheumatology.

[2]  F. Becce,et al.  Clinical Utility of Multi‐Energy Spectral Photon‐Counting Computed Tomography in Crystal Arthritis , 2019, Arthritis & rheumatology.

[3]  L. Duley,et al.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.

[4]  W. Lems,et al.  Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis , 2018, BMC Rheumatology.

[5]  Hyon K. Choi,et al.  Effects of Febuxostat in Early Gout , 2017, Arthritis & rheumatology.

[6]  S. Nicolaou,et al.  Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol , 2017, Annals of the rheumatic diseases.

[7]  A. Gerards,et al.  No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission , 2017, Rheumatology.

[8]  J. Budzik,et al.  Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study , 2017, Arthritis Research & Therapy.

[9]  C. Viroli,et al.  Development and First Validation of a Disease Activity Score for Gout , 2016, Arthritis care & research.

[10]  A. Ogdie,et al.  Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises , 2016, Arthritis care & research.

[11]  F. Perez-Ruiz,et al.  Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout , 2015, Arthritis care & research.

[12]  M. Lell,et al.  Tophus resolution with pegloticase: a prospective dual-energy CT study , 2015, RMD Open.

[13]  S. Nicolaou,et al.  Artifacts in dual-energy CT gout protocol: a review of 50 suspected cases with an artifact identification guide. , 2014, AJR. American journal of roentgenology.

[14]  C. Díaz-Torné,et al.  Concerns of Patients With Gout Are Incompletely Captured by OMERACT-Endorsed Domains of Measurement for Chronic Gout Studies , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[15]  B. Krauss,et al.  Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. , 2014, Seminars in arthritis and rheumatism.

[16]  W. Taylor,et al.  Do Patient Preferences for Core Outcome Domains for Chronic Gout Studies Support the Validity of Composite Response Criteria? , 2013, Arthritis care & research.

[17]  V. Bykerk,et al.  The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. , 2012, Rheumatology.

[18]  S. Nicolaou,et al.  Dual energy CT in gout: a prospective validation study , 2012, Annals of the rheumatic diseases.

[19]  J. Singh,et al.  Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10 , 2011, The Journal of Rheumatology.

[20]  N. Dalbeth,et al.  The Experience and Impact of Living With Gout: A Study of Men With Chronic Gout Using a Qualitative Grounded Theory Approach , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[21]  J. Singh,et al.  Outcome Domains for Studies of Acute and Chronic Gout , 2009, The Journal of Rheumatology.

[22]  H. Genberg,et al.  A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation , 2009, Transplantation.

[23]  S. Nicolaou,et al.  Dual energy computed tomography in tophaceous gout , 2008, Annals of the rheumatic diseases.

[24]  M. Netea,et al.  Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1β by mononuclear cells through a caspase 1-mediated process , 2008, Annals of the rheumatic diseases.

[25]  E. Pascual,et al.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.

[26]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[27]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[28]  W. Downie,et al.  Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. , 1987, British journal of clinical pharmacology.

[29]  D. Mccarty,et al.  Preliminary criteria for the classification of the acute arthritis of primary gout. , 1977, Arthritis and rheumatism.

[30]  D. Mccarty,et al.  Identification of urate crystals in gouty synovial fluid. , 1961, Annals of internal medicine.

[31]  P. Hench.  DIAGNOSIS AND TREATMENT OF GOUT AND GOUTY ARTHRITIS , 1941 .

[32]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..